ArticleThe Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association2026
Methadone Versus Buprenorphine/Naloxone: Treatment Outcome Differences Among Individuals Receiving Medications for Opioid Use Disorders in Rural Treatment Settings-A 1-Year Retrospective Cohort Study.
Article in The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMedication for opioid use disorder (MOUD) is the gold standard of treatment for opioid use disorder (OUD). Methadone and buprenorphine have shown to be the most effective MOUD, yet little is known about the compared efficacy when treating OUD in community-based rural treatment settings. This study aims to explore treatment outcome differences among patients initiating methadone or buprenorphine/naloxone in community-based rural treatment programs.
methodsData for this 1-year retrospective cohort study were extracted from electronic medical records of 561 individuals initiating treatment between January 2019 and December 2019 at four MOUD clinics located in rural Oregon. Between-group comparisons were conducted using chi-square for dichotomous variables and ANOVA for continuous variables. Kaplan Meier and generalized estimating equations were used to determine treatment retention and opioid use over time.
resultsOf the 561 patients, 74.5% were dispensed methadone while 25.5% were prescribed buprenorphine/naloxone. Those dispensed methadone were more likely to be unemployed (57.7% vs. 44.8%, p = 0.01) and diagnosed with severe OUD (93.5% vs. 83.9%, p = 0.04). There were no significant group differences on other treatment intake demographics nor opioid use or treatment retention over a 12-month period. Clinic site was a significant predictor of proportion of negative urine tests.
conclusionBoth methadone and buprenorphine/naloxone performed comparably well in reducing opioid use and retaining patients in treatment. In comparison to medication type, clinical site and time in treatment had a larger impact on participant outcomes. These findings suggest that the use of both methadone and buprenorphine/naloxone should be encouraged in the context of rural MOUD treatment programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.